WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2011 Global Citi Health Care Conference on March 2, 2011 at 3:00 p.m. and at the 31st Annual Cowen and Company Health Care Conference on March 7, 2011, at 3:15 p.m. The Citi Conference will be held at the Hilton New York Hotel in New York, and the Cowen Conference will be held at the Boston Marriott Copley Place Hotel in Boston.
The presentations will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and with ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.